These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

745 related articles for article (PubMed ID: 29116596)

  • 1. Antibody-Drug Conjugates for the Treatment of Solid Tumors: Clinical Experience and Latest Developments.
    Nagayama A; Ellisen LW; Chabner B; Bardia A
    Target Oncol; 2017 Dec; 12(6):719-739. PubMed ID: 29116596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody-Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review.
    Lambert JM; Morris CQ
    Adv Ther; 2017 May; 34(5):1015-1035. PubMed ID: 28361465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody-Drug Conjugates for Cancer Treatment.
    Lambert JM; Berkenblit A
    Annu Rev Med; 2018 Jan; 69():191-207. PubMed ID: 29414262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody-Drug Conjugates: A Clinical Pharmacy Perspective on an Emerging Cancer Therapy.
    Jerjian TV; Glode AE; Thompson LA; O'Bryant CL
    Pharmacotherapy; 2016 Jan; 36(1):99-116. PubMed ID: 26799352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody-targeted drugs and drug resistance--challenges and solutions.
    Shefet-Carasso L; Benhar I
    Drug Resist Updat; 2015 Jan; 18():36-46. PubMed ID: 25476546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical perspective: Antibody-drug conjugates for the treatment of HER2-positive breast cancer.
    Najminejad Z; Dehghani F; Mirzaei Y; Mer AH; Saghi SA; Abdolvahab MH; Bagheri N; Meyfour A; Jafari A; Jahandideh S; Gharibi T; Amirkhani Z; Delam H; Mashatan N; Shahsavarani H; Abdollahpour-Alitappeh M
    Mol Ther; 2023 Jul; 31(7):1874-1903. PubMed ID: 36950736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody drug conjugates.
    Bakhtiar R
    Biotechnol Lett; 2016 Oct; 38(10):1655-64. PubMed ID: 27334710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody-drug conjugates for cancer.
    Chau CH; Steeg PS; Figg WD
    Lancet; 2019 Aug; 394(10200):793-804. PubMed ID: 31478503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Drug-Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody-Maytansinoid Conjugates.
    Sun X; Ponte JF; Yoder NC; Laleau R; Coccia J; Lanieri L; Qiu Q; Wu R; Hong E; Bogalhas M; Wang L; Dong L; Setiady Y; Maloney EK; Ab O; Zhang X; Pinkas J; Keating TA; Chari R; Erickson HK; Lambert JM
    Bioconjug Chem; 2017 May; 28(5):1371-1381. PubMed ID: 28388844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody-drug conjugates: A promising novel therapeutic approach in lung cancer.
    Desai A; Abdayem P; Adjei AA; Planchard D
    Lung Cancer; 2022 Jan; 163():96-106. PubMed ID: 34942494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predicting Response to Antibody Drug Conjugates: A Focus on Antigens' Targetability.
    Ascione L; Crimini E; Trapani D; Marra A; Criscitiello C; Curigliano G
    Oncologist; 2023 Nov; 28(11):944-960. PubMed ID: 37665782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody-Drug Conjugates in Gynecologic Cancer.
    Karpel HC; Powell SS; Pothuri B
    Am Soc Clin Oncol Educ Book; 2023 May; 43():e390772. PubMed ID: 37229642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985).
    Xu Z; Guo D; Jiang Z; Tong R; Jiang P; Bai L; Chen L; Zhu Y; Guo C; Shi J; Yu D
    Eur J Med Chem; 2019 Dec; 183():111682. PubMed ID: 31563805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent Advances in Antibody-Drug Conjugates for Breast Cancer Treatment.
    Deng S; Lin Z; Li W
    Curr Med Chem; 2017; 24(23):2505-2527. PubMed ID: 28554322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody-Drug Conjugates: The New Frontier of Chemotherapy.
    Ponziani S; Di Vittorio G; Pitari G; Cimini AM; Ardini M; Gentile R; Iacobelli S; Sala G; Capone E; Flavell DJ; Ippoliti R; Giansanti F
    Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32752132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody-Drug Conjugates for Breast Cancer.
    Marmé F
    Oncol Res Treat; 2022; 45(1-2):26-36. PubMed ID: 34915488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody-drug conjugates: Promising and efficient tools for targeted cancer therapy.
    Nasiri H; Valedkarimi Z; Aghebati-Maleki L; Majidi J
    J Cell Physiol; 2018 Sep; 233(9):6441-6457. PubMed ID: 29319167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sacituzumab govitecan, a novel, third-generation, antibody-drug conjugate (ADC) for cancer therapy.
    Goldenberg DM; Sharkey RM
    Expert Opin Biol Ther; 2020 Aug; 20(8):871-885. PubMed ID: 32301634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody-Drug Conjugates for Cancer Therapy.
    Hafeez U; Parakh S; Gan HK; Scott AM
    Molecules; 2020 Oct; 25(20):. PubMed ID: 33081383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody-drug conjugates: present and future.
    Beck A; Reichert JM
    MAbs; 2014; 6(1):15-7. PubMed ID: 24423577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.